Electromagnetic Compatibility (EMC) of Medical Devices

June 7, 2022

Guidance Document

June 2022

This guidance document provides the FDA’s recommendations on testing to assess the electromagnetic compatibility of medical devices and information to include in the labeling. This guidance applies to medical devices, including in vitro diagnostics, and accessories that are electrically powered or have functions or sensors that are implemented using electrical or electronic circuitry. The recommendations are intended to promote consistency and facilitate efficient review of electromagnetic compatibility in device submissions.

FDA recognizes and anticipates that the Agency and industry may need up to 1 year to perform activities to operationalize the policies within the guidance, only for in vitro diagnostic products. Since this guidance generally reflects current practice for the assessment of EMC for other device types, but some activities to fully operationalize the policies are needed (e.g., updates to eSTAR), FDA intends to implement this guidance 60 days after issuance for device types within the scope of this guidance, excluding in vitro diagnostic products. If new information regarding electromagnetic compatibility as outlined in this guidance is not included in a premarket submission for an in vitro diagnostic received by FDA before or up to 1 year after the publication of this guidance or for other device types within the scope of this guidance before or up to 60 days after the publication of this guidance, CDRH staff does not generally intend to request such information during the review of the submission. CDRH does, however, intend to review any such information if submitted.

Download the Final Guidance Document

Read the Federal Register Notice

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.




FDA North America

June 7, 2022

Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions

Guidance Document Guidance for Industry and Food and Drug Administration Staff JUNE 2022 This guidance document provides FDA's recommendations on the information, technical performance assessment,...

Read More
FDA North America

June 7, 2022

Drug Products, Including Biological Products, that Contain Nanomaterials

Guidance for Industry April 21, 2022 Nanotechnology can be used in a broad array of FDA-regulated products, such as human drug products, including those that are biological products.3 Nanotechnology...

Read More
Agency Alerts General Regulatory

June 7, 2022

FDA Modifies Guidance on Certain OTC Drugs Containing Acetaminophen

Background On April 29, 2009, FDA announced a final rule that required labels of certain over-the-counter (OTC) pain relievers and fever reducers to include warnings about potential safety risks,...

Read More